Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors

References

• Ameri P, Ferone D. Diffuse endocrine system, neuroendocrine tumors and immunity: what’s new? Neuroendocrinology. 2012;95(4):267–276.
   PubMed Web of Science ®Google Scholar
• Lawrence B, BI G, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18.
   PubMed Web of Science ®Google Scholar
• Fraenkel M, Kim M, Faggiano A, et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–63.
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
   PubMed Web of Science ®Google Scholar
• O’Toole D, Kianmanesh R, ENETS CM. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2016;103(2):117–118.
   PubMed Web of Science ®Google Scholar
• Pape UF, Perren A, Niederle B, et al. Barcelona consensus conference participants. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95:135–156.
   Google Scholar
• Niederle B, UF P, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–138.
   PubMed Web of Science ®Google Scholar
• Falconi M, Eriksson B, Kaltsas G, et al. Consensus guidelines update for the management of functional p-NETs (F-p-NETs) and non-functional p-NETs (NF-p-NETs). Neuroendocrinology. 2016;103(2):153–171.
   PubMed Web of Science ®Google Scholar
• Herrera‑Martinez AD, Hofland J, Hofland LJ, et al. Targeted systemic treatment of neuroendocrine tumors: current options and future perspectives. Drugs. 2019;79:21–42.
   PubMed Web of Science ®Google Scholar
• Mougey AM, Adler DG. Neuroendocrine tumors: review and clinical update. Hosp Physician. 2007;51:12–20.
   Google Scholar
• Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104(10):764–777.
   PubMedGoogle Scholar
• Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25(2):186–192.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Osamura RY, Kloppel G, et al. World health organization, international agency for research on cancer. who classification of tumours of endocrine organs. 4. Geneva: World Health Organization; 2017.
   Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. Jan.
   PubMed Web of Science ®Google Scholar
• Kruljac I, Pape UF. The classification of neuroendocrine neoplasms: “Neuroendocrine carcinomas” revisited – a 2017 update and future perspectives. Endocr Oncol Metab. 2017;3(2):37–42.
   Google Scholar
• Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–762.
   PubMed Web of Science ®Google Scholar
• Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401.
   PubMed Web of Science ®Google Scholar
• Araujo PB, Cheng S, Mete O, et al. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One. 2013 Apr 19;8(4):e61538.
   PubMed Web of Science ®Google Scholar
• Elvebakken H, Perren A, Scoazec JY, et al. A consensus developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations. Neuroendocrinology .2020 Online ahead of print.
   Google Scholar
• Capurso G, Rinzivillo M, Bettini R, et al. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg. 2012;99(11):1480–1486.
   PubMed Web of Science ®Google Scholar
• Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2017;46(6):715–731.
   PubMed Web of Science ®Google Scholar
• Mitchell WD, Findlay JM, Prescott RJ, et al. Bile acids in the diarrhoea of ileal resection. Gut. 1973 May;14(5):348–353.
   PubMed Web of Science ®Google Scholar
• BartoliniI, Bencini L, Risaliti M, et al. Current management of pancreatic neuroendocrine tumors: from demolitive surgery to observation. Gastroenterol Res. 2018;Pract.2018:9647247.
   Web of Science ®Google Scholar
• Panzuto F, Massironi S, Partelli S, et al. Gastro-entero-pancreatic neuroendocrine neoplasia: the rules for non-operative management. Surg Oncol. 2020;35:141–148.
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009;27:4656–4663.
   Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al., Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3): 224–233.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–188.
   PubMed Web of Science ®Google Scholar
• Laskaratos FM, Armeni E, Shah H, et al. Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms. Endocrine. 2020;67(1):233–242.
   PubMed Web of Science ®Google Scholar
• Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Oberg KE, O’Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657–666.
   PubMed Web of Science ®Google Scholar
• Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075–5078.
   PubMed Web of Science ®Google Scholar
• Pavel M, Valle JW, Eriksson B, et al. Antibes consensus conference participants. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy - biotherapy and novel targeted agents. Neuroendocrinology. 2017;105(3):266–280.
   PubMed Web of Science ®Google Scholar
• Strosberg J, El-Haddad G, Wolin E, et al., Phase 3 trial of 1lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2): 125–135.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos L, Laskaratos FM, Kalligeros M, et al. Antiproliferative effect of above-label doses of somatostatin analogs for the management of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2020 Online ahead of print
   PubMedGoogle Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47.
   PubMed Web of Science ®Google Scholar
• Michael M, Garcia-Carbonero R, Weber MM, et al. The antiproliferative role of lanreotide in controlling growth of neuroendocrine tumors: a systematic review. Oncologist. 2017;22(3):272–285.
   PubMed Web of Science ®Google Scholar
• Lima-Martínez MM, López-Méndez G. Mangupli R: bradicardia sinusal inducida por octreotide en un varón con acromegalia. Endocrinol Nutr. 2013;60:e7–e9.
   PubMedGoogle Scholar
• Dilger J, Rhoe E, Que F. Sprung J: octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor. Anesth Analg. 2004;98:318–320.
   PubMed Web of Science ®Google Scholar
• Herrington AM, George KW. Moulds CC: octreotide-Induced Bradycardia. Pharmacotherapy. 1998;18(2):413–416.
   PubMed Web of Science ®Google Scholar
• Caplin M, Pavel M, Cwikla JB, et al. Antitumor effects of lanreotide for pancreatic and intestinal neuroendocrine tumors: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191–199.
   PubMed Web of Science ®Google Scholar
• Lamberti G, Faggiano A, Brighi N, et al. Nonconventional doses of somatostatin analogs in patients with progressing well-differentiated neuroendocrine tumor. J ClinEndocrinolMetab. 2020;105(1):dgz035.
   PubMed Web of Science ®Google Scholar
• Lamarca Α, McCallum L, Nuttal L, et al. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Rev Gastroenterol Hepatol. 2018;12(7):723–727.
   PubMed Web of Science ®Google Scholar
• Rinzivillo M, De Felice I, Magi L, et al. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. Pancreatology. 2020;20(5):875–879.
   PubMed Web of Science ®Google Scholar
• Plöckinger U, Dienemann D. Quabbe HJ: gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab. 1990;71(6):1658–1662.
   PubMed Web of Science ®Google Scholar
• Haugen B. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23(6):793–800.
   PubMed Web of Science ®Google Scholar
• Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol. 1991;79(Suppl 1):74–77.
   PubMed Web of Science ®Google Scholar
• Yao J, Guthrie K, Moran C, et al. SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol. 2015;33(15_suppl):4004.
   Web of Science ®Google Scholar
• Mirvis E, Mandair D, Garcia-Hernandez J, et al. Role of interferon-alpha in patients with neuroendocrine tumors: a retrospective study. Anticancer Res. 2014;34(11):6601–6607.
   PubMed Web of Science ®Google Scholar
• Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000;62(Suppl 1):92–97.
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Böhmig M, et al.; International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689–2696.
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761–771.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Baum U, Hahn EG, et al. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res. 2006;26(1):8–13.
   PubMed Web of Science ®Google Scholar
• Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57(6):1379–1390.
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316–1323.
   PubMed Web of Science ®Google Scholar
• Kulke MH, O’ Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705–714.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Hörsch D, Caplin ME, et al., Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1): 14–23.
   PubMed Web of Science ®Google Scholar
• Pavel M, Hörsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–1519.
   PubMed Web of Science ®Google Scholar
• Pavel M, Gross DJ, Benavent M, et al., Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase III trial. Endocr Relat Cancer. 2018;25(3): 309–322.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Joish VN, Giacalone S, et al. TELEPRO: patient-reported carcinoid syndrome symptom improvement following initiation of telotristat ethyl in the real world. Oncologist. 2019 Nov;24(11):1446–1452.
   PubMed Web of Science ®Google Scholar
• Anthony LB, Kulke MH, Caplin ME, et al. Long-term safety experience with telotristat ethyl across five clinical studies in patients with carcinoid syndrome. Oncologist. 2019 Aug;24(8):e662–e670.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al., Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6): 501–513.
   PubMed Web of Science ®Google Scholar
• Wiedmann MW, Mossner J. Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. Clin Med Insights Oncol. 2012;6:381–393.
   PubMedGoogle Scholar
• Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (nen) and nen of unknown primary site. Neuroendocrinology. 2016;103(2):172–185.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al., Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6): 514–523.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al., Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808): 2005–2012.
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, et al., Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT- 4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022): 968–977.
   PubMed Web of Science ®Google Scholar
• Bainbridge HE, Larbi E, Middleton G. Symptomatic control of neuroendocrine tumours with everolimus. Horm Cancer. 2015;6(5–6):254–259.
   PubMed Web of Science ®Google Scholar
• Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28(2):339–343.
   PubMed Web of Science ®Google Scholar
• Trelinska J, Dachowska I, Kotulska K, et al. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anticancer Drugs. 2015;26(4):437–442.
   PubMed Web of Science ®Google Scholar
• Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond). 2018;18(3):212–218.
   PubMed Web of Science ®Google Scholar
• Valle JW, Faivre S, Hubner RA, et al. Practical management of Sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev. 2014;40(10):1230–1238.
   PubMed Web of Science ®Google Scholar
• Funakoshi T. Shimada YJ: risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol. 2013;52(4):691–702.
   PubMed Web of Science ®Google Scholar
• Cives M, Strosberg J. Radionuclide therapy for neuroendocrine tumors. Curr Oncol Rep. 2017;19(2):9.
   PubMed Web of Science ®Google Scholar
• Pool SE, Krenning E, Koning GA, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010;40(3):209–218.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17(1):R53–73.
   PubMed Web of Science ®Google Scholar
• Severi S, Grassi I, Nicolini S, et al. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–557.
   PubMed Web of Science ®Google Scholar
• Bushnell DL Jr, O’ Dorisio TM, O’ Dorisio MS, et al. 90 Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652–1659.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Kunz PL, Hendifar A. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020. Online ahead of print. doi:10.1007/s00259-020-04709-x
   PubMed Web of Science ®Google Scholar
• Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015;42(13):1955–1963.
   PubMed Web of Science ®Google Scholar
• Forrer F, Uusijärvi H, Storch D, et al. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005;46(8):1310–1316.
   PubMed Web of Science ®Google Scholar
• Vaughan E, Machta J, Walker M, et al. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Br J Radiol. 2018;91(1091):20180041.
   PubMed Web of Science ®Google Scholar
• Brabander T, Van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [(177)Lu DOTA(0), Tyr(3)] octreotate in patients with Gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–4624.
   PubMed Web of Science ®Google Scholar
• Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5–19.
   PubMed Web of Science ®Google Scholar
• Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54(11):1857–1861.
   PubMed Web of Science ®Google Scholar
• Pencharz D, Walker M, Yalchin M, et al. Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET. Nucl Med Commun. 2017;38(7):593–600. Jul.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–194.
   PubMed Web of Science ®Google Scholar
• Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;117(20):4617–4622.
   PubMed Web of Science ®Google Scholar
• Walenkamp AME, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35(3):228–236.
   PubMed Web of Science ®Google Scholar
• Tang LH, Basturk O, Sue JJ, et al. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and Poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–1202.
   PubMed Web of Science ®Google Scholar
• Vélayoudom-Céphise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649–657.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–160.vol. Article ID mds276.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Halfdanarson TR. Management of well-differentiated high-grade (g3) neuroendocrine tumors. Curr Treat Options Oncol. 2019;20(9):74.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Grace Kong G, Simona Grozinsky-Glasberg S. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer. 2020;27(3): R67–R77. Mar.
   PubMed Web of Science ®Google Scholar
• Turner NC, Strauss SJ, Sarker D, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer. 2010;102(7):1106–1112.
   PubMed Web of Science ®Google Scholar
• JR S, RL F, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–275.
   PubMed Web of Science ®Google Scholar
• Fine R, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663–670.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J clin oncol. 2006;24(3):401–406.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J clin oncol. 2006;24(18):4044
   PubMed Web of Science ®Google Scholar
• Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J clin oncol. 2012;30(24):2963–2968.
   PubMed Web of Science ®Google Scholar
• Hadoux J, Malka D, Planchard D, et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015;22(3):289–298.
   PubMed Web of Science ®Google Scholar
• Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19(6):751–757.
   PubMed Web of Science ®Google Scholar
• Saif MW, Kaley K, Brennan M, et al. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. J Pancreas. 2013;14(5):498–501.
   PubMedGoogle Scholar
• Sahu Α JΜ, Lai-Kwon J, Thai A, et al. CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumors: a single centre experience. J Oncol. 2019;2019:9032753.
   PubMedGoogle Scholar
• Chatzellis E, Angelousi A, Daskalakis K, et al. Activity and safety of standard and prolonged capecitabine/temozolomide administration in patients with advanced neuroendocrine neoplasms. Neuroendocrinology. 2019;109(4):333–345.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991 Jul 15;68(2):227–232.
   PubMed Web of Science ®Google Scholar
• Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–176.
   PubMed Web of Science ®Google Scholar
• Eriksson J, Stalberg P, Nilsson A, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg. 2008;32(5):930–938.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441–451.
   PubMed Web of Science ®Google Scholar
• Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002;89(10):1206–1222.
   PubMed Web of Science ®Google Scholar
• de Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol. 2000;175(6):1619–1625.
   PubMed Web of Science ®Google Scholar
• Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Intervent Radiol. 2013;30(1):28–38.
   PubMed Web of Science ®Google Scholar
• Davar J, Connolly HML, Caplin ME. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69(10):1288–1304.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol. 1999;2:S31–8. 10Suppl.
   Google Scholar
• Pavel ME, Singh S, Strosberg J, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(10):1411–1422.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177 Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 Sep 1;36(25):2578–2584.
   PubMed Web of Science ®Google Scholar
• Laskaratos FM, Caplin M. Treatment challenges in and outside a network setting: gastrointestinal neuroendocrine tumours. Eur J Surg Oncol. 2019 Jan;45(1):52–59.
   PubMed Web of Science ®Google Scholar
• Metz DC, Choi J, Jonathan Strosberg J, et al. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2012;19(4):306–313.
   PubMed Web of Science ®Google Scholar
• Magi L, Mazzuca F, Rinzivillo M, et al. Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center. J Clin Med. 2019;8(6):910.
   Web of Science ®Google Scholar